Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lanadelumab - Takeda

Drug Profile

Lanadelumab - Takeda

Alternative Names: Anti-plasma kallikrein mAb; Anti-plasma kallikrein monoclonal antibody; DX-2930; Lanadelumab-flyo; SHP 643; TAK-743; TAKHZYRO

Latest Information Update: 13 May 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dyax
  • Developer Dyax; Shire; Takeda
  • Class Antivirals; Eye disorder therapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Plasma kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Phase I/II COVID 2019 infections
  • Phase I COVID-19 pneumonia
  • Discontinued Diabetic macular oedema

Most Recent Events

  • 30 Apr 2021 Takeda completes a phase I/II trial in COVID-2019 infections in Netherlands (IV) (NCT04422509)
  • 16 Mar 2021 9318144: DT, KDM, Intro update
  • 12 Mar 2021 Preregistration for Hereditary angioedema (In adolescents, In children, In the elderly, In adults, Prevention) in Japan (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top